Review
Fast Facts
Contact Info and Support
Traffic information
| Category | Metrics | Meaning |
|---|---|---|
| Ratings | Global Rank | - |
| Country Code | - | |
| Country Rank | - | |
| Category Rank | - | |
| Engagement metrics | Visits | 0 |
| Bounce Rate | 0 | |
| Pageviews per Visit | 0 | |
| Avg. Visit Duration | 0 | |
| Estimated monthly visits | January 2026 | 0 |
| February 2026 | 0 | |
| March 2026 | 0 | |
| Traffic sources | Social | - |
| Paid Referrals | - | |
| - | ||
| Referrals | - | |
| Search | - | |
| Direct | - |
About StatonFxc
StatonFxc operates under the domain statonfxc.com and is listed by the U.S. Securities and Exchange Commission (“SEC”) as an unregistered soliciting entity that falsely claims to be licensed or located in the United States; this alert was issued on April 7, 2022 (). The company is not registered with the U.S. SEC, nor is it registered as a futures commission merchant or foreign exchange dealer with the Commodity Futures Trading Commission (CFTC), nor a member of the National Futures Association (NFA); no regulatory authorisation exists in U.S. official registries ().
The operator has been identified issuing unrealistic promises of high returns—such as 30.5%, 50.5%, and even 99.5% profit within a week—without offering any legitimate mechanism or explanation for how these returns are generated, a known red flag in scam operations (). Additional assessments confirm that StatonFxc remains unregulated and is considered a high‑risk or potentially fraudulent entity ().
Pros and cons
Pros
- No verified regulatory credentials, licensure, platforms, account types, or trading conditions found to support any legitimate offering.
Cons
- Not registered or licensed by any recognised regulator (SEC, CFTC, NFA).
- Subject of a Public Alert issued by the U.S. SEC for being an unregistered soliciting entity.
- Website domain
statonfxc.comhas experienced suspension or unavailability, indicating unreliable operation. - Unrealistic profit claims typical of fraudulent investment schemes.
- Classified in analyses as “not recommended” or high‑risk by multiple sources based on regulatory status.













